0000000000041208

AUTHOR

Rick L. Haas

0000-0003-4834-4331

showing 2 related works from this author

Health-Related Quality of Life Issues Experienced by Thoracic and Breast Sarcoma Patients: A Rare and Understudied Group

2021

Thoracic and breast sarcomas constitute a rare subgroup within the sarcoma population. There is limited knowledge about their health-related quality of life (HRQoL) and a valid disease-specific HRQoL instrument is lacking. This qualitative study aimed to investigate the HRQoL issues experienced by a small group of thoracic and breast sarcoma patients. Semi-structured interviews with 19 thoracic and four breast sarcoma patients were conducted and thematically analysed. Physical issues mentioned by both groups were fatigue, sleep disturbances, pain, wound infections, and symptoms related to chemotherapy and radiotherapy. Tightness in the back and restrictions in performing tasks above arm hei…

medicine.medical_specialtychest sarcomaBreast SarcomaPopulationbreast sarcomaSocial issuesArticleRC0254Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14]All institutes and research themes of the Radboud University Medical CenterSDG 3 - Good Health and Well-beingQuality of lifemedicinethoracic sarcomaSocial determinants of healtheducationeducation.field_of_studybusiness.industryRGeneral Medicinemedicine.diseaseMental healthhealth-related quality of lifeMoodpatient-reported outcomesPhysical therapyMedicineSarcomabusinessRare cancers Radboud Institute for Health Sciences [Radboudumc 9]Journal of Clinical Medicine
researchProduct

Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (…

2015

ABSTRACT The DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) aims to provide recommendations for definitions of time-to-event end points in cancer randomized controlled trials. We relied on a consensus method based on a multidisciplinary panel of experts to develop these guidelines for trials on sarcomas and gastrointestinal stromal tumors. Background The use of potential surrogate end points for overall survival, such as disease-free survival (DFS) or time-to-treatment failure (TTF) is increasingly common in randomized controlled trials (RCTs) in cancer. However, the definition of time-to-event (TTE) end points is rarely precise and lacks unif…

medicine.medical_specialtyConsensusTime FactorssarcomaDelphi TechniqueEndpoint Determination[SDV]Life Sciences [q-bio]Disease-Free Survivallaw.invention03 medical and health sciencesgastrointestinal stromal tumors0302 clinical medicineRandomized controlled trialSDG 3 - Good Health and Well-beinglawMultidisciplinary approachTerminology as TopicmedicineHumansMedical physicsTreatment Failureguidelinestime-to-event end pointComputingMilieux_MISCELLANEOUSRandomized Controlled Trials as Topic030304 developmental biologyEvent (probability theory)0303 health sciencesEnd pointGiSTSurrogate endpointbusiness.industryefficacy measureCancerHematologymedicine.disease3. Good healthOncologyResearch Design030220 oncology & carcinogenesisrandomized controlled trialDisease ProgressionRadiologySarcomabusiness
researchProduct